Evidence map›Paper›PMID 34259837›Full record

ArticleInternational journal of epidemiology2022

Plasma concentrations of persistent organic pollutants and pancreatic cancer risk.

Miquel Porta, Magda Gasull, José Pumarega, Hannu Kiviranta, Panu Rantakokko, Ole Raaschou-Nielsen, Ingvar A Bergdahl, Torkjel Manning Sandanger, Antoni Agudo, Charlotta Rylander and 43 more

Open access · greenAbstract read
In one paragraph

Article in International journal of epidemiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

53 authors at 20 institutions in 12 countries.

Miquel PortaHospital del Mar Institute of Medical Research (IMIM PSMar), Barcelona, Catalonia, Spain.ORCID 0000-0003-1684-7428
Magda GasullHospital del Mar Institute of Medical Research (IMIM PSMar), Barcelona, Catalonia, Spain.
José PumaregaHospital del Mar Institute of Medical Research (IMIM PSMar), Barcelona, Catalonia, Spain.
Hannu KivirantaDepartment of Health Security, National Institute for Health and Welfare, Kuopio, Finland.
Panu RantakokkoDepartment of Health Security, National Institute for Health and Welfare, Kuopio, Finland.
Ole Raaschou-NielsenDanish Cancer Society Research Center, Copenhagen, Denmark.
Ingvar A BergdahlDepartment of Biobank Research, Umeå University, Umeå, Sweden.
Torkjel Manning SandangerDepartment of Community Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.
Antoni AgudoUnit of Nutrition and Cancer, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain.
Charlotta RylanderDepartment of Community Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.
Therese Haugdahl NøstDepartment of Community Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.
Carolina Donat-VargasCardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Dagfinn AuneDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Alicia K HeathDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Lluís CireraSpanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Fernando Goñi-IrigoyenSpanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Juan AlguacilSpanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Àlex Giménez-RobertHospital del Mar Institute of Medical Research (IMIM PSMar), Barcelona, Catalonia, Spain.
Anne TjønnelandDanish Cancer Society Research Center, Copenhagen, Denmark.
Malin SundDepartment of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden.
Kim OvervadDepartment of Public Health, Aarhus University, Aarhus, Denmark.
Francesca Romana ManciniCESP, Faculté de médecine (USVQ), Université Paris-Sud, INSERM, Université Paris-Saclay, Villejuif, France.
Vinciane ReboursPancreatology Department, Beaujon Hospital, AP-HP, Clichy, France.
Marie-Christine Boutron-RuaultCESP, Faculté de médecine (USVQ), Université Paris-Sud, INSERM, Université Paris-Saclay, Villejuif, France.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Matthias B SchulzeDepartment of Molecular Epidemiology, German Institute of Human Nutrition Potsdam, Rehbruecke, Nuthetal, Germany.
Antonia TrichopoulouHellenic Health Foundation, Athens, Greece.
Domenico PalliCancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network-ISPRO, Florence, Italy.
Sara GrioniEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Rosario TuminoCancer Registry and Histopathology Department, "Civic-M.P. Arezzo" Hospital, ASP Ragusa, Ragusa, Italy.
Alessio NaccaratiMolecular and Genetic Epidemiology Unit, Italian Institute for Genomic Medicine (IIGM), Turin, Italy.
Salvatore PanicoDipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.
Roel VermeulenInstitute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands.
J Ramón QuirósPublic Health Directorate, Asturias, Spain.
Miguel Rodríguez-BarrancoSpanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Sandra M Colorado-YoharSpanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
María-Dolores ChirlaqueSpanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Eva ArdanazSpanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Nick WarehamMRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Tim KeyCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Mattias JohanssonInternational Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.
Neil MurphyInternational Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.
Pietro FerrariInternational Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.
Inge HuybrechtsInternational Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.
Veronique ChajesInternational Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.
Carlos Alberto GonzalezUnit of Nutrition and Cancer, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain.
Bas Bueno-de-MesquitaDepartment for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Marc GunterInternational Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.
Elisabete WeiderpassInternational Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.
Elio RiboliDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Eric J DuellOncology Data Analytics Program, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain.
Verena KatzkeDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Paolo VineisDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.ORCID 0000-0001-8935-4566
Centre international de recherche sur le cancer · FRUniversitat Autònoma de Barcelona · ESImperial College London · GBInstitut d'Investigació Biomédica de Bellvitge · ESUiT The Arctic University of Norway · NODanish Cancer Society · DKFinnish Institute for Health and Welfare · FIGerman Cancer Research Center · DEInstituto Murciano de Investigación Biosanitaria · ESItalian institute for Genomic Medicine · ITUmeå University · SEUniversité Paris-Sud · FRAarhus University · DKAzienda Usl 8 Arezzo · ITBasque Government · ESCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESFederico II University Hospital · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITGobierno del Principado de Asturias · ESHellenic Health Foundation · GR

Funding

Cancer Research UK 14136Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MC_UU_00006/1Medical Research Council MR/N003284/1Medical Research Council MR/S019669/1World Health Organization 001
6 · The paper itself

Abstract

backgroundFindings and limitations of previous studies on persistent organic pollutants (POPs) and pancreatic cancer risk support conducting further research in prospective cohorts.

methodsWe conducted a prospective case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Participants were 513 pancreatic cancer cases and 1020 matched controls. Concentrations of 22 POPs were measured in plasma collected at baseline.

resultsSome associations were observed at higher concentrations of p, p'-DDT, trans-nonachlor, β-hexachlorocyclohexane and the sum of six organochlorine pesticides and of 16 POPs. The odds ratio (OR) for the upper quartile of trans-nonachlor was 1.55 (95% confidence interval 1.06-2.26; P for trend = 0.025). Associations were stronger in the groups predefined as most valid (participants having fasted >6 h, with microscopic diagnostic confirmation, normal weight, and never smokers), and as most relevant (follow-up ≥10 years). Among participants having fasted >6 h, the ORs were relevant for 10 of 11 exposures. Higher ORs were also observed among cases with microscopic confirmation than in cases with a clinical diagnosis, and among normal-weight participants than in the rest of participants. Among participants with a follow-up ≥10 years, estimates were higher than in participants with a shorter follow-up (for trans-nonachlor: OR = 2.14, 1.01 to 4.53, P for trend = 0.035). Overall, trans-nonachlor, three PCBs and the two sums of POPs were the exposures most clearly associated with pancreatic cancer risk.

conclusionsIndividually or in combination, most of the 22 POPs analysed did not or only moderately increased the risk of pancreatic cancer.

Indexed as

Environmental PollutantsPancreatic NeoplasmsPesticidesPolychlorinated BiphenylsCase-Control StudiesHumansPersistent Organic PollutantsEnvironmental PollutantsPersistent Organic PollutantsPesticidesPolychlorinated Biphenylsbiomarkersenvironmental healthmethodsPancreatic cancerpersistent organic pollutants

Identifiers

PMID34259837
PMCPMC9082788
OpenAlexW3181689026

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.